Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration Resistant Prostate Cancer

NCT01503229 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01503229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01503229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration Resistant Prostate Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2012
Completion date
March 12, 2020
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-resistant prostate cancer, metastatic prostate carcinoma, recurrent prostate carcinoma, stage iv prostate adenocarcinoma